Danny H. Lewis

Lewis Consulting, Inc. provides pharmaceutical services. The private company is based in Raleigh, NC.

The Controlled Release Society is a private company that focuses on providing fundamental delivery research, development, regulatory science, and clinical translation. The company is based in St. Paul, MN. The company was founded by Agis Kydonieus.

PR Pharmaceuticals, Inc. develops, manufactures and commercialization of bioactive compounds in sustained-release formulations. It offers injectable and biodegradable formulations to treat chronic diseases. It produces drug delivery technologies for human and animal health. Its products include Insular, Pulmolar, and Somalar. The company was founded in 1998 by Steve R. Howe & William R. Lance and is located in Fort Collins, CO

Part of DURECT Corp., Southern BioSystems, Inc. is a company that manufactures and develops biodegradable polymer and non-polymer drug delivery systems. The company is based in Birmingham, AL. The company was founded by Alan H. Dean. Southern BioSystems was acquired by DURECT Corp. on April 30, 2001 for $13.64 million.

Part of Nektar Therapeutics, Shearwater Corp. is a company that provides research services focused on health care applications of advanced PEGylation. The company is based in Huntsville, AL. The company was founded by James R. Hudson, J. Milton Harris. Shearwater was acquired by Nektar Therapeutics on July 02, 2001 for $164.50 million.

Part of Alkermes Plc, Medisorb Technologies International LP develops drug delivery systems. The company is based in Cincinnati, OH. The company was founded by Danny H. Lewis. Medisorb Technologies International was acquired by Alkermes, Inc., part of Alkermes Plc from September 16, 2011 on March 11, 1996 for $5 million.

Egen, Inc. operates as a clinical stage biopharmaceutical company which develops novel proprietary nanoparticle delivery technology for therapeutic use. Egen's technology platform is very broad, including polymer, cationic lipid, and molecular biology-based approaches to delivery of nucleic acid and anti-cancer drugs. The primary activities of the company are the application of the TheraPlas and TheraSilence platforms to the treatment of human disease. Egen's lead candidate, EGEN-001, is in Phase II clinical testing for ovarian cancer and in Phase I clinical testing for colorectal cancer. In addition, Egen is pursuing pre-clinical development of its TheraSilence RNAi delivery program for multiple disease applications, as well as other novel disruptive technologies focused on creating the next generation of synthetic nanoparticle delivery systems and nucleic acid-based therapies. It is also active in pursuing partnerships and working with external collaborators to further develop its delivery technology for multiple applications. Egen offers cutting-edge research services relating to non-viral polymeric gene carrier systems, and other approaches for the delivery of nucleic acid and anti-cancer drugs. The company's synthetic biocompatible delivery vehicles can be used to deliver therapeutic genes, inhibitory RNA (RNAi), and small molecules by protecting the therapeutic cargo from degradation, promoting uptake by target cells, and facilitating intracellular trafficking. Egen was founded in 2002 by Sung Wan Kim and is headquartered in Huntsville, AL.